CBDY · XBRL financial data

Target Group financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CBDY's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers1,0461,915*1,9202,2755411,856*1,4001,246500735*8791,381
Cost of goods and services sold454year only1,110806173777*630500235448*688753
Gross profit592—8101,4693681,078*771745264287*192628
Total operating expenses648597*699568606736*617608520544*502612
Interest income————922*161700*——
Interest expense338351*349273268263*251264267263*288289
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(357)(185)*(193)667(529)216*(108)(220)(479)(552)*(550)(240)
Earnings per share, basic USD per share(0.00)0.00*(0.00)0.00(0.00)0.00*(0.00)(0.00)(0.00)0.00*(0.00)(0.00)
Earnings per share, diluted USD per share(0.00)0.00*(0.00)0.00(0.00)—(0.00)(0.00)(0.00)0.00*(0.00)(0.00)
Weighted average shares, basic thousands of shares617,026617,026*617,026617,026617,026617,026*617,026617,026617,026617,026*617,026617,026
Weighted average shares, diluted thousands of shares617,026507,826*617,026617,026617,026—617,026617,026617,026617,026*617,026617,026

Balance sheet

CSV

Fiscal quarters (CBDY's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents4547457541,7421,2931,87878284634610921014
Accounts receivable1281,032894734677646312313446455522
Inventory1,8931,2167385281,0108827859771,4241,6691,6771,716
Total current assets2,5853,0941,6932,8232,5923,1022,4152,3102,1822,3302,4812,371
Property and equipment, net5,4285,4305,0684,8114,6864,1863,9713,9833,7253,5543,3093,029
Right-of-use asset504747444338373734333028
Goodwill264269263260264248248261256260256251
Total assets8,3278,8417,0717,9387,5857,5746,6706,5916,1976,1776,0765,678
Current portion of long-term debt2,1267,8807,6927,6157,7217,2447,2507,6407,4877,6047,4777,334
Total current liabilities8,41114,58912,98313,22213,49213,09612,3439,96912,74013,38213,82413,603
Long-term debt5,583—00————————
Lease liability, non-current1,2301,2241,1601,1121,089985946954891858795731
Total liabilities15,18315,81414,14314,33414,58214,08113,28913,62113,63114,24014,62014,334
Accumulated deficit(30,922)(31,107)(31,301)(30,634)(31,163)(30,947)(31,055)(31,275)(31,754)(32,307)(32,857)(33,097)
Total stockholders' equity(6,855)(6,973)(7,073)(6,397)(6,997)(6,508)(6,619)(7,030)(7,434)(8,063)(8,544)(8,655)
Total liabilities and equity8,3278,8417,0717,9387,5857,5746,6706,5916,1976,1776,0765,678
Common shares outstanding (cover page) thousands of shares617,026617,026617,026617,026617,026617,026617,026617,026617,026617,026617,026617,026

Cash flows

CSV

Fiscal quarters (CBDY's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(357)(185)*(193)667(529)216*(108)(220)(479)(552)*(550)(240)
Net cash from operating activities(570)*290*774981*(329)*736*(570)484*(506)*(251)*(94)(223)*
Net cash from investing activities(10)*(18)*(3)16*(143)*(50)*2816*24*13*(40)(7)*
Net cash from financing activities1*(2)*(742)5*1*5*(557)(499)*(8)*(1)*24131*

Compare with peers

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Target Group141,381(223)*617.0M0.1 quarters 10-QJun 30, 2026
Creative Medical Technology Holdings8,7140(1,472)*6.6M5.9 quarters 10-QJun 30, 2026
Soligenix9,811not reported(1,707)*21.8M5.7 quarters 10-QJun 30, 2026
Aspira Women's Health47717(2,010)*46.6M0.2 quarters 10-QJun 30, 2026
Matinas BioPharma Holdings761not reported(1,836)*14.7M0.4 quarters 10-QJun 30, 2026
Synlogic13,1830(922)*12.2M14.3 quarters 10-QJun 30, 2026
Viskase Holdings7,91190,131(11,205)*14.3M0.7 quarters 10-QJun 30, 2026
China Pharma Holdings305948(33)*43.0M9.3 quarters 10-QJun 30, 2026
Xenetic Biosciences6,472661(875)*2.3M7.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.